Table 1.
Comparison of the clinical characteristics of all β-TM patients with their controls
| Variables | β-TM patients (n = 111) | Control subjects (n = 60) | p value |
|---|---|---|---|
| Age (years) | 10.0 (8.0–13.0)* | 12.0 (10.0–14.0)* | 0.029 |
| Hb (g/L) | 65.0 (54.0–77.0) | 130.0 (123.0–139.0) | <0.001 |
| Hct (%) | 20.8 (18.1–24.5) | 39.4 (36.8–41.6) | <0.001 |
| WBC × 109 (cells/L) | 10.53 (7.69–30.16) | 6.63 (5.83–7.81) | <0.001 |
| Platelet × 109 (cells/L) | 271.0 (205.0–530.0) | 272.0 (218.8–317.8) | 0.204 |
| TB (μmol/L) | 34.2 (27.3–49.5) | 9.41 (3.42–13.68) | <0.001 |
| DB (μmol/L) | 6.84 (6.84–10.3) | 3.42 (1.71–3.42) | <0.001 |
| AST (U/L) | 65.0 (56.0–95.0) | 20.0 (15.3–24.8) | <0.001 |
| ALT (U/L) | 81.0 (69.0–123.0) | 12.0 (10.0–15.8) | <0.001 |
| ALP (U/L) | 130.0 (103.0–176.0) | 71.0 (56.3–84.0) | <0.001 |
| TC (mmol/L) | 2.94 (2.45–3.46) | 4.50 (4.19–4.88) | <0.001 |
| TG (mmol/L) | 1.66 (1.41–2.06) | 0.73 (0.60–1.06) | <0.001 |
| LDL-C (mmol/L) | 1.42 (1.16–1.88) | 2.46 (2.21–3.04) | <0.001 |
| HDL-C (mmol/L) | 0.65 (0.49–0.83) | 1.59 (1.37–1.75) | <0.001 |
| VLDL-C (mmol/L) | 0.550 (0.447–0.669) | 0.241 (0.194–0.351) | <0.001 |
| Ferritin (μg/L) | 2,622.3 (1,686.0–5,000.0) | 60.4 (48.3–75.8) | <0.001 |
| MDA (μmol/L) | 9.0 (6.4–14.8) | 2.78 (2.24–3.18) | <0.001 |
| RC-MDA/gHb (μmol/L) | 7.55 (6.23–8.94) | 3.83 (1.15–3.98) | <0.001 |
| TAC (mmol TroloxEquiv/L) | 0.470 (0.000–0.520) | 5.55 (4.55–5.77) | <0.001 |
p value <0.05, significant; * median (interquartile)
Hb hemoglobin, Hct hematocrit, TB total bilirubin, DB direct bilirubin, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol, MDA malondialdehyde, RC red blood cell, /g Hb per gram hemoglobin, TAC total antioxidant capacity